Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In June 2018, the Company entered into a license agreement with Emory (the Emory License Agreement), pursuant to which Emory granted the Company a worldwide, sublicensable license under certain of its intellectual property rights to make, have made, develop, use, offer to sell, sell, import and export products containing certain compounds relating to Emory's hepatitis B virus capsid assembly modulator technology, for all therapeutic and prophylactic uses.”
FILING10-K0001193125-26-092614cik 0001799448
“KU Leuven granted to the Company an exclusive (including as to KU Leuven), worldwide license under certain of KU Leuven's know-how, and certain joint patents and joint know-how, to manufacture and commercialize the licensed products for the treatment, diagnosis or detection of viral infections in humans.”
FILING10-K0001193125-26-092614cik 0001799448
“In 2023, the Company was awarded a contract of $ 8.5 million by the National Institute of Allergies and Infectious Diseases (NIAID) for research to target coronaviruses.”
FILING10-K0001193125-26-092614cik 0001799448
“In 2022, the Company was awarded a grant of $ 1.1 million by the National Institutes of Health (NIH) for research to target coronaviruses.”
FILING10-K0001193125-26-092614cik 0001799448
“Collaboration revenue included recognition of our upfront payments pursuant to an agreement and amendment with Merck Sharp & Dohme Corp, that were terminated in prior years.”
FILING10-K0001193125-26-092614cik 0001799448
“Under the terms of the agreement, the Company received an upfront payment of $ 7.0 million, less withholding taxes of $ 1.1 million from Amoytop.”
FILING10-K0001193125-26-092614cik 0001799448
“Revenue from customers was $2.2 million for the year ended December 31, 2025, compared to $3.6 million for the year ended December 31, 2024, a decrease of $1.4 million, primarily due to the collaboration and license agreement with Amoytop, the collaboration portion of which ended in November 2025.”
FILING10-K0001193125-26-092614cik 0001799448
“Specific clinical and nonclinical studies for the ALG-097558 program and the follow up compound, are now also being funded with federal funds from the NIAID, NIH, Department of Health and Human Services, under Contract No. 75N93023C00052.”
FILING10-K0001193125-26-092614cik 0001799448
“Preclinical activities for our coronavirus program were partially funded through a grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program through the Metropolitan AntiViral Drug Accelerator (MAVDA) consortium.”
FILING10-K0001193125-26-092614cik 0001799448
“Preclinical activities for our coronavirus program were partially funded through a grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program through the Metropolitan AntiViral Drug Accelerator (MAVDA) consortium.”
FILING10-K0001193125-26-092614cik 0001799448
“AGILE University of Liverpool, a UK government supported platform trial (MRC and Wellcome Trust funding), is sponsoring and performing a Phase 2 study in standard and high-risk COVID‑19 patients evaluating ALG‑097558 as monotherapy or in combination with remdesivir (NCT04746183).”
FILING10-K0001193125-26-092614cik 0001799448
“In this area of focus, we are exploring small molecule coronavirus 3CL protease inhibitors (PIs) in collaboration with the Rega Institute at Katholieke Universiteit Leuven (KU Leuven), the Center for Innovation and Stimulation of Drug Discovery (CISTIM) and the Centre for Drug Design and Discovery (CD3).”
FILING10-K0001193125-26-092614cik 0001799448
“In this area of focus, we are exploring small molecule coronavirus 3CL protease inhibitors (PIs) in collaboration with the Rega Institute at Katholieke Universiteit Leuven (KU Leuven), the Center for Innovation and Stimulation of Drug Discovery (CISTIM) and the Centre for Drug Design and Discovery (CD3).”
FILING10-K0001193125-26-092614cik 0001799448
“Specific clinical and nonclinical studies for the ALG‑097558 program and the follow up compound are now also being funded with federal funds from the NIAID, NIH, Department of Health and Human Services, under Contract No. 75N93023C00052.”
FILING10-K0001193125-26-092614cik 0001799448
“In June 2018, we entered into a license agreement with Emory (the Emory License Agreement), pursuant to which Emory granted us a worldwide, sublicensable license under certain of its intellectual property rights to make, have made, develop, use, offer to sell, sell, import and export products containing certain compounds relating to Emory's hepatitis B virus capsid assembly modulator technology, for all therapeutic and prophylactic uses.”
FILING10-K0001193125-26-092614cik 0001799448
“Preclinical activities for our coronavirus program were partially funded through a grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program through the Metropolitan AntiViral Drug Accelerator (MAVDA) consortium.”
FILING10-K0001193125-26-092614cik 0001799448
“Preclinical activities for our coronavirus program were partially funded through a grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program through the Metropolitan AntiViral Drug Accelerator (MAVDA) consortium.”
FILING10-K0001193125-26-092614cik 0001799448
“Current costs for development in China are being funded by Amoytop, who maintain rights in China, Taiwan, Hong Kong and Macau.”
FILING10-K0001193125-26-092614cik 0001799448
“The Company determined that the ADC Therapeutics (ADCT) agreement falls within the scope of ASC 606.”
FILING10-K0001193125-26-092614cik 0001799448
“Preclinical activities for our coronavirus program were partially funded through a grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program through the Metropolitan AntiViral Drug Accelerator (MAVDA) consortium.”
FILING10-K0001193125-26-092614cik 0001799448
Watchlist prices, news filtered to it, and its next report on your desk.
Aligos Therapeutics, Inc. has 12 disclosed suppliers and 8 disclosed customers. Each one is named in an SEC filing, either Aligos Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 5.01 · gapped below the open, then crossed back over prior close. High/low 5.10 at 4:15 am ET, 4.79 at 4:00 am ET.
Aligos Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
ALGS (Aligos Therapeutics, Inc.) has 12 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ADCT −2.70%, in healthcare.